As debate intensifies in the U.S. over abortion, a new survey finds nearly half of all women support alternatives to visiting a medical facility in order to obtain the abortion medicine to terminate pregnancies. And the findings suggest there is potential to expand access to abortion care, if regulators can be persuaded to loosen regulations governing access to the medicine, according to the researchers.

Currently, women in the U.S. must obtain mifepristone at a doctor’s office, clinic, or hospital under a risk management program required by the Food and Drug Administration. The restrictions were imposed when the drug was approved in 2000 and stipulate Mifeprex may not be sold in pharmacies and health care providers must complete a certification process.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy